Impact of the Number of Prior Lines of Therapy and Prior Perioperative Chemotherapy in Patients Receiving Salvage Therapy for Advanced Urothelial Carcinoma: Implications for Trial Design

• Published in: Clinical genitourinary cancer Vol. 13; no. 1; pp. 71 - 79
• Main Authors: Pond, G.R, Bellmunt, J, Rosenberg, J.E, Bajorin, D.F, Regazzi, A.M, Choueiri, T.K, Qu, A.Q, Niegisch, G, Albers, P, Necchi, A, Di Lorenzo, G, Fougeray, R, Wong, Y.-N, Sridhar, S.S, Ko, Y.-J, Milowsky, M.I, Galsky, M.D, Sonpavde, G
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.02.2015
• Subjects: Advanced; Aged; Clinical Trials, Phase II as Topic; Drug Therapy - methods; Hematology, Oncology and Palliative Medicine; Humans; Middle Aged; Number of prior regimens; Perioperative Care; Prior perioperative chemotherapy; Prognosis; Prospective Studies; Regression Analysis; Salvage therapy; Salvage Therapy - methods; Survival Analysis; Treatment Outcome; Urologic Neoplasms - drug therapy; Urologic Neoplasms - mortality; Urology; Urothelial carcinoma; Advanced; Prognosis; Prior perioperative chemotherapy; Number of prior regimens; Urothelial carcinoma; Salvage therapy
• ISSN: 1558-7673; 1938-0682
• DOI: 10.1016/j.clgc.2014.06.004

Micro-Abstract This analysis of patients from prospective trials of salvage therapy for advanced urothelial carcinoma did not identify a prognostic effect for number of prior lines of therapy and prior perioperative chemotherapy. Performance status, hemoglobin, liver metastasis, and time from prior chemotherapy were prognostic for outcomes. These findings allow trials to use uniform eligibility criteria, which will enhance accrual and improve interpretability.